| Summary: | 碩士 === 中國醫藥大學 === 醫學檢驗生物技術學系碩士班 === 98 === Part I:Chemokine CXCL12（SDF-1） was thought to act through its “canonical” receptor, CXCR4, to promote the growth of primary tumors and progression to metastatic disease in many cancers. Recently, several reports have documented that CXCR7/RDC1 also plays as a chemokine receptor for CXCL12. So we want to investigate the potential role of CXCL12 and the responsive receptor in OSCC. From examining 112 primary cancer specimens of OSCC patients by immunohistochemistry staining, we found that 59% cases expressed chemokine CXCL12, 80% cases expressed CXCR4 and 87％ cases expressed CXCR7. In all of the 23 metastatic lymph nodes the metastatic oral cancer cells expressed both CXCR4 and CXCR7 receptors, and 52% cases expressed chemokine CXCL12. From exploring seven OSCC cell lines by western blot and flow cytomestry, six cell lines expressed chemokine CXCL12, three cell lines expressed receptor CXCR7, and all of the seven cell lines expressed CXCR4. Furthermore, CXCL12 can stimulate oral cancer cell proliferation under serum starvation condition. And the CXCL12-induced proliferation effect can be blocked by addition of CXCR4 or CXCR7 antibodies. We concluded that CXCL12 mediates the cellular proliferation in the progression of OSCC through both CXCR4 and CXCR7 receptors.
Part II:Cysteine-rich 61 (Cyr61), one of the CCN gene family, is a secreted and matrix-associated protein. It is involved in many cellular activities such as growth and differentiation. Most of CCN family membranes can regulate the cell motility, division and adhesion in various cancer by interaction of integrin. However, the effect of Cyr61 on progression in human oral squamous cell carcinoma (OSCC) is mostly unknown. Here, we investigated the role of Cyr61 in the progression of OSCC. From examining 100 primary cancer specimens of OSCC patients by immuohistochemistry staining, we found that Cyr61 highly expressed in OSCC specimens. We suggest that Cyr61 have significant correlations with the progression of oral squamous cell carcinoma.
|
|---|
